Volver a Agenda
Session 3, Track A: HC/HTA Collaboration – Updates and Insights
Session Chair(s)
Louise Blythe, MSc
VP & Head, Regulatory Affairs
Bayer Inc. Canada, Canada
Tharany Ganesh
Head, Regulatory Affairs
AstraZeneca Canada Inc., Canada
Myriam Antoun, MBA
Global Head of FSP Regulatory Affairs
PPD, Part of Thermo-Fisher, Canada
Time to patient access for Canadian medicines is a lengthy process. Pharmaceutical Regulatory Affairs professionals play a crucial role in this process. There have been recent initiatives undertaken to facilitate time to patient access for Canadian medicines via collaboration amongst industry, Health Canada, Health Technology Assessment agencies and government (policy makers). This session will provide updates and insights on the current initiatives and progress. This session will also address role of Regulatory Affairs in generating the value story and proactive ways to positively impact the process.
Learning Objective : - Understand the initiatives industry is taking in progressing time to patient access for Canadian medicines
- Understand progresses made on collaboration between Health Canada and Health Technology Assessment agencies and recent introduction of innovative approaches to facilitate access (eg, Real World Evidence and time-limited recommendation)
¿Tiene una cuenta?